In the published article, there was an error in the legend for Figures 2, 3 as published. The legends for Figures 2, 3 were placed in the wrong order. The legend for ...

The small molecules in question are ASTX029, an ERK1/2 inhibitor that has completed a phase 2 study, and ASTX295 an MDM2 antagonist that has undergone a phase 1 trial. Both candidates have ...

Background Fibrolamellar carcinoma (FLC), a rare and fatal liver cancer lacking effective drug therapy, is driven by the DNAJ-PKAc fusion oncoprotein. However, the underlying mechanism of DNAJ-PKAc’s ...

None of the cases exhibited positive IgG4 plasma cells or MDM2 amplification. Table 1. Clinicopathologic features of all reported cases of the perinephric myxoid pseudotumors of fat. At present, the ...